NCT06795412View on ClinicalTrials.gov

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 6, 2027

Study Completion Date

December 6, 2027

Conditions
Advanced Solid Tumours
Interventions
DRUG

PYX-201

Intravenous (IV) infusion.

DRUG

pembrolizumab

IV infusion.

Trial Locations (7)

22031

RECRUITING

NEXT Virginia, Fairfax

33612

RECRUITING

Moffitt Cancer Center, Tampa

77030

RECRUITING

University of Texas - M.D. Anderson Cancer Center, Houston

77054

RECRUITING

NEXT Oncology Houston, Houston

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

92093

RECRUITING

University of California San Diego, San Diego

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Pyxis Oncology, Inc

INDUSTRY

NCT06795412 - Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter